Chief Executive Officer
For several years, Martin has worked with global business development within Novozymes, where he was responsible for commercializing new biotech platforms to new markets.
Responsibilities included building global partnerships and strategy development & execution.
Martin has also worked for Boston Consulting Group in both Europe and Australia and on projects involving M&A due diligence, strategy development, operational effectiveness, and PMI management.
Finally, Martin has execution and management experience from roles such as Head of Sales within Hilti Denmark and as a First Lieutenant of the Reserve in the Danish Army.
CSO and Co-Founder
Hans did his doctoral and postdoctoral training in biotechnology at the NNF Center for Biosustainability at the Technical University of Denmark with additional training from Harvard University in the group of Professor George Church and UC Berkeley / the Joint Bio-Energy Institute in the group of professor Jay Keasling.
Hans holds personal awards for Exceptional Achievements (McKinsey & Co.), Top 10 European Biotech Entrepreneurs under 30, and has authored numerous scientific papers and patents. Hans co-founded Biosyntia and currently heads the R&D.
Ph.D., Research Scientist
Luisa is a metabolic engineering scientist at Biosyntia. Luisa holds a B.Sc. with Honors in Chemistry from the University of Arizona and an M.Sc. and Ph.D. in Chemistry and Chemical Biology from Harvard University, where she was a recipient of a National Science Foundation Graduate Research Fellowship and worked in the laboratory of Prof. Daniel Kahne.
Before joining Biosyntia, Luisa spent three years as a postdoctoral fellow in James Liao’s Metabolic Engineering and Synthetic Biology Laboratory at UCLA, where she led an ARPA-E-funded research team in engineering novel carbon fixation cycles into bacteria.
Analytical Chemist & Lab Manager
Linda is an analytical chemist at Biosyntia. Linda holds an M.Sc. in Analytical Chemistry and a Ph.D. in Pharmaceutical Chemistry from the University of Helsinki.
Linda has gained broad expertise in metabolomics and lipidomics from working as a research analytical chemist at Steno Diabetes Center Copenhagen (SDCC) for almost four years before joining Biosyntia in 2018. Additionally, Linda brings valuable knowledge to the team concerning starting up analytical laboratories and setting up new analytical methods since these have been her main responsibilities throughout the past years.
At Biosyntia, Linda is responsible for setting up new analytical methods and techniques for the team to gain deeper knowledge in the biological and fermentation processes being performed.
Ph.D., Downstream Processing Project Lead
Markus holds a Ph.D. in Organic Chemistry from Linköping University (Sweden) and gained experience from the pharmaceutical industry at AstraZeneca and biopharmaceutical CDMO AGC Biologics. He served the biotech firm Glycom A/S for +10 years, where he was leading the R&D Downstream Process department bringing novel purification processes of Human Milk Oligosaccharides from R&D lab into commercial production.
Anne is a Ph.D. candidate at Biosyntia and holds an M.Sc.Eng degree with Honors in Biotechnology from the Technical University of Denmark, Delft Technical University and Nanyang Technical University.
Anne has been involved in several projects concerning metabolic engineering and synthetic biology including the student-driven, double award-winning DTU-iGEM project 2014.
Ben holds a B.Sc. degree from the University of California, San Diego in General Biology.
Ben brings to Biosyntia ten years of experience in the sustainable chemicals industry. Most recently, he worked in the fermentation department of a renewable chemical research company working on producing intermediate chemicals from alternative feedstocks, where he was part of the team that brought two compounds to commercial scale. Responsibilities included process development and troubleshooting as well as process scale-up from lab-scale to 200,000 L, with site work in Italy and Germany.
Ben is working on developing a fermentation process at Biosyntia, turning small scale results achieved by the molecular biology team into an industrially relevant and scalable fermentation-platform.
Ph.D., Research Scientist
Carlos is a protein and metabolic engineering scientist at Biosyntia.
Carlos holds a “cum laude” Ph.D. in molecular biotechnology from the Max Planck Institute and the Technical University Munich.
During his Ph.D. at the lab of Nediljko Budisa, Carlos developed new approaches to improve proteins based on genetic code engineering (xenobiology). He then did postdoctoral training in biocatalysis and protein directed evolution at the lab of Manfred T. Reetz.
Carlos is interested in the potential of synthetic biology for developing real-world applications using protein, metabolic and genome engineering guided by systems biology approaches.
Dóra is a PhDcandidate at Biosyntia and holds a B.Sc. Degree from the University of Szegedspecializing in Biochemical engineering and a M.Sc. Degree in Biotechnology from Chalmers University of Technology, specializing in metabolic engineering.
Her previous experience involves partaking in the 2016 iGEM competitionas one of the team leaders of the gold medal winning team Chalmers Gothenburg.During her master’s thesis Dóra was working on modulating transcription factorexpression in yeast in order to provide better cofactor availability for fattyacid production. Dóra also worked as a research engineer with developingribosome profiling workflows for cyanobacteria cultures at the Royal Instituteof Technology in Stockholm.
Dóra’s PhD ispart of the MSCA-ITN SynCrop with 10 academic and 6 industrial partners. The main objective of SynCrop is toinvestigate modular and tunable synthetic circuits and foster the developmentof novel production platforms for food additives.
Jonathan is an analytical chemistry trainee and holds an M.Chem degree in Chemistry with Honours from the University of Manchester, having also done an exchange at the University of Freiburg.
Jonathan has experience in various analytical techniques, having completed projects concerning chromatographic method development and inorganic synthesis.
Aster is a master student studying biotechnology with a double specialization in process engineering and molecular biotechnology at the Wageningen University. Aster had worked on projects involving the enzymatic production of vanillin and modeling starch oxidation.
M.Sc. Eng., Research Scientist
Nils is a metabolic engineering research scientist at Biosyntia and holds a M.Sc. Eng. degree from the Technical University of Denmark and the Novo Nordisk Foundation Center for Biosustainability.
He has published research experience with synthetic biology in yeast and genetic stability in metabolically engineered bacteria. He was awarded the Novo Scholarship for his master thesis on the latter. Nils is fascinated by the possibilities that metabolic engineering, biodiversity and evolution provide for establishment of a sustainable, bio-based economy.
Belinda is an intern and Master Thesis candidate at Biosyntia and holds a B.Sc. degree in Biomolecular Engineering from the Technical University of Darmstadt, Germany.
She is an alumna of the Femtec Career-Building Program, a one and a half year scholarship for talented young women involved in science, economy, and engineering that expands soft skills in project work, management, and leadership.
Mandy has completed a bachelor in Life Science & Technology at the University of Leiden and the TU Delft. She is currently finishing her M.Sc. at the TU Delft, and is following the track ‘Cell factory’. Mandy is interested in the metabolic engineering of microorganisms as a sustainable alternative for the petrochemical industry.
M.Sc., Research Scientist
Katie is a Research Scientist at Biosyntia and holds a B.A. / B.Sc. (Hons) degree from the University of Auckland specializing in Biology and Geography.
Joining the Biosyntia team, Katie brings with her seven years of industrial microbial fermentation experience. Her prior experience has been at a microbial gas fermentation company, where she was based both in New Zealand and Chicago as well as completing industrial site work in China and Japan. There she was involved in leading novel process development, upscaling the process from 1 L to 16,000 L and troubleshooting new strain development. She has several published scientific articles and patents.
Katie is working on developing a fermentation process at Biosyntia, turning small scale results achieved by the molecular biology team into an industrially relevant and scalable fermentation-platform.
Research Scientist Metabolic Engineering
Bo is a metabolic engineering scientist at Biosyntia. Bo holds a B.Sc. in Chemical Engineering and an M.Sc.Eng degree in Biotechnology from the Technical University of Denmark. He obtained his Ph.D. at University of Copenhagen at the DNRF Center of Excellence for Dynamic Molecular Interactions (DynaMo).
Bo has a broad expertise within different heterologous expression systems, where he has worked with plant, yeast, filamentous fungi and bacteria.
The majority of his work has revolved around establishing stable expression systems for high-throughput metabolic engineering of complex biosynthetic pathways.
M.Sc., Research Scientist
Daniel is a research scientist at Biosyntia, working in strain engineering, assay development and automation of data analysis. He holds an M.Sc. in Industrial and Environmental Biotechnology from the University of Aveiro. During his academic formation, Daniel participated in exchange programs twice: at Vytautas Magnus University and Federal University of Paraná.
His research background focused mostly in applied and environmental microbiology on which he has several published scientific articles. Daniel is fascinated by microbial ecology and biotechnology, data science and biosustainability.
Anna-Maria is Downstream process trainee at Biosyntia and holds a M.Sc. Eng. degree in Biotechnology from the Technical University of Denmark, and a MEng degree in ChemicalEngineering from the National Technical University of Athens.
She has experience from research projects within protein glycoscience covering heterologous expression, purification and characterization of carbohydrate-active enzymes and binding proteins. Moreover, she has research experience in biochemical engineering with process development and economic feasibility and scale-up of microbially produced biomolecules.
Anna-Maria aspires to develop innovative manufacturing bioprocesses for a more sustainable and greener future.
Søren was CSO of Novozymes/Novo Nordisk Enzyme Business 1994-2000 and Managing Partner of Novo Ventures and Novo Seeds 2000-2015. Søren co-founded “Dansk Biotek” (Danish association of Biotech Companies) in 1987 and was chairman from 1994-2012. He has extensive leadership and operational experience and has for the last 15 years been involved in Board work in various Danish and international companies in the life science sector.Show moreShow less
Co-Founder & Board Member
Morten is a Professor at the Department of Systems Biology at the Technical University of Denmark and group leader at NNF CfB. Morten Sommer did his doctorial research in Biophysics at Harvard University and his post doctorial training at Harvard Medical School. Morten Sommer has founded 3 other biotech companies (Synercure 2011, Microlytic 2006, Formbion 2004), has authored numerous scientific papers, and is the inventor on >10 issued patents. For his research accomplishments, Morten Sommer has received numerous awards, including the research prizes of Direktør Ib Henriksens Fonds Forskerpris (2010) and the Hartmann Foundation (2006).Show moreShow less
Henrik has through more than 30 years been involved in the establishment and growth of the international biotech and life science industry in Denmark. Henrik has worked in Chr. Hansen, Novozymes, Novo Nordisk, and Nordisk Gentofte, from where he has substantial business, strategy and scientific experience in industries ranging from biopharmaceuticals, food ingredients, animal feed, dietary supplement, and infant nutrition. He has been responsible for development of several commercialized products both within the biopharmaceutical- and the industrial biotechnology area, and he has led the creation of successful business operations with high and very profitable growth rates.Show moreShow less
Thomas joined Novo Holdings in September 2017 as Principal in Novo Seeds. He focuses on investments in the area of industrial biotechnology, also known as white biotechnology. Prior to joining Novo Seeds, Thomas worked as independent consultant and as Senior Business Development Manager in Novozymes. He has advised startup companies and research institutions on biotechnology and business development. In addition, he introduced advanced yeast technology to the biofuel industry and built a portfolio of biochemical projects in Novozymes. Earlier in his career, Thomas played a leading role in raising venture capital and developing the nutraceutical product portfolio in the metabolic engineering company Fluxome Sciences. He also held positions in biotechnology research and process engineering at Toftejorg (Alfa Laval), Carlsberg and BASF.Thomas obtained his MSc in chemical engineering from the Technical University of Denmark in 2001 and a PhD in metabolic engineering and bioinformatics in 2005 from the same university. He also has two graduate diplomas in business administration from Copenhagen Business School, marketing management in 2007 and finance in 2010.Show moreShow less
Joško Bobanović joined Sofinnova Partners in 2010 as Partner dedicated to activities in industrial biotech. He focuses on early stage deals in Europe and North America with applications in chemicals, agriculture, food, feed and synthetic biology. Joško sits on the boards of Metgen, Synthace, Cellucomp, Comet Bio, DNA Script and Biosyntia. Prior to joining Sofinnova he spent eight years in venture capital with iNovia Capital in Montreal, Canada. Prior to his venture capital career he created an internet startup and a software company. After completing his PhD studies Joško developed real-time ocean forecasting systems still used at Environment Canada for coastal ocean management. Joško holds a BSc. in physics from University of Zagreb, a PhD in physical oceanography from Dalhousie University and an MBA in finance and marketing from McGill University.Show moreShow less
Has over 30 years of experience with biobased vitamin production from Roche Vitamins and DSM Nutritional products. As a world leading authority on biobased vitamins Dr. Hohmann has developed biobased processes for various compounds, including. vitamin B2 and vitamin C.Show moreShow less
Is head of the Institute of Technical Biochemistry and professor at the University of Stuttgart. Prior to his university career he was Vice President of Research and head of the biocatalysis research group at BASF SE, Ludwigshafen. He is active on several advisory boards, editorial boards as well as scientific societies.Show moreShow less
Novo Holding is a global investor in the Life Science industry and invests at all stages of development. Today, Novo Holdings invests and manages assets valued at more than €47 billion and holds 76 portfolio companies. Working out of Copenhagen, San Francisco, and Boston, Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Established in 1999, Novo Holdings is the holding company of the Novo Group and manages the Novo Nordisk Foundation’s investment assets. Novo Holdings is the major shareholder in the Novo Group companies Novo Nordisk A/S and Novozymes A/S.
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together 12 highly experienced investment professionals from all over Europe, the US, and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs.
Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs and has backed nearly 500 companies over 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over 1,8 billion euros under management. For more information, please visit: www.sofinnova.fr